DR. OZLEM GOKER-ALPAN M.D.
Prescription History 1427270313
Pediatrics in Fairfax, VA
NPI Status: Active since May 02, 2007
Contact Information
11212 WAPLES MILL RD STE 100
FAIRFAX, VA
ZIP 22030
Phone: (571) 308-1900
Fax: (571) 577-8859
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. OZLEM GOKER-ALPAN M.D., an active Pediatrics specialist practicing in Fairfax, VA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 66 documented patient claims. Among these therapy options, the most frequently utilized medication is Fabrazyme, which accounts for 44 claims alone.
Cerdelga
Generic Formulation: Eliglustat TartrateSpecialty: Pediatric MedicineProvider Avg Cost Per Claim
$32,465.06
State Avg Cost Per Claim
$32,101.99
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used for long-term treatment of a certain rare genetic problem (Gaucher's disease). Eliglustat works by decreasing the amount of a certain natural fatty substance (glucosylceramide) that builds up due to this condition. This can improve symptoms of Gaucher's disease, such as bruising, tiredness, pain in the joints/bones, and a swollen liver/spleen.
Fabrazyme
Generic Formulation: Agalsidase BetaSpecialty: Pediatric MedicineProvider Avg Cost Per Claim
$17,029.86
State Avg Cost Per Claim
$16,078.02
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat a certain inherited disorder (Fabry disease) that causes buildup of a certain fat substance (GL-3) in some parts of your body. Worsening of this disorder can lead to kidney disease, heart attack, or stroke. Agalsidase beta works by replacing an enzyme that your body lacks, which helps break down the fat substance (GL-3) in your body. This can help prevent symptoms such as pain (especially in the hands and feet), dark red spots on the skin, a decreased ability to sweat, cloudiness of the front part of the eye, stomach/intestinal problems, ringing in the ears (tinnitus), and hearing loss.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. OZLEM GOKER-ALPAN M.D. provides transparency into local medical care patterns within Fairfax, VA.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
